CorVel (NASDAQ:CRVL) Hits New 12-Month Low – Time to Sell?

CorVel Corp. (NASDAQ:CRVL) shares reached a new 52-week low during trading on Friday . The stock traded as low as $65.95 and last traded at $65.9250, with a volume of 11636 shares changing hands. The stock had previously closed at $67.67.

Analyst Upgrades and Downgrades

CRVL has been the topic of several research reports. Wall Street Zen downgraded CorVel from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Weiss Ratings restated a “hold (c)” rating on shares of CorVel in a research report on Tuesday, October 14th. One analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, the company presently has an average rating of “Hold”.

CorVel Price Performance

The business’s 50 day simple moving average is $71.76 and its 200-day simple moving average is $82.08. The stock has a market capitalization of $3.37 billion, a P/E ratio of 32.38 and a beta of 1.07.

CorVel (NASDAQ:CRVL) last posted its quarterly earnings results on Tuesday, November 4th. The business services provider reported $0.54 earnings per share for the quarter. CorVel had a return on equity of 31.72% and a net margin of 11.28%.The company had revenue of $239.64 million for the quarter.

Insider Activity

In related news, EVP Mark E. Bertels sold 1,200 shares of CorVel stock in a transaction that occurred on Wednesday, November 19th. The shares were sold at an average price of $72.35, for a total transaction of $86,820.00. Following the transaction, the executive vice president owned 2,594 shares of the company’s stock, valued at $187,675.90. This trade represents a 31.63% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director R Judd Jessup sold 7,076 shares of the business’s stock in a transaction that occurred on Tuesday, November 11th. The shares were sold at an average price of $76.94, for a total transaction of $544,427.44. Following the transaction, the director owned 115,045 shares of the company’s stock, valued at approximately $8,851,562.30. This represents a 5.79% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 11,733 shares of company stock valued at $894,686 over the last 90 days. Corporate insiders own 44.56% of the company’s stock.

Hedge Funds Weigh In On CorVel

Several institutional investors and hedge funds have recently made changes to their positions in the company. Hantz Financial Services Inc. bought a new stake in shares of CorVel in the 2nd quarter valued at $32,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. bought a new stake in shares of CorVel in the second quarter worth about $37,000. Federated Hermes Inc. raised its position in shares of CorVel by 147.4% during the third quarter. Federated Hermes Inc. now owns 381 shares of the business services provider’s stock worth $29,000 after purchasing an additional 227 shares during the period. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of CorVel during the third quarter worth about $31,000. Finally, Quarry LP lifted its holdings in shares of CorVel by 218.6% during the 3rd quarter. Quarry LP now owns 513 shares of the business services provider’s stock valued at $40,000 after purchasing an additional 352 shares in the last quarter. Institutional investors and hedge funds own 51.36% of the company’s stock.

CorVel Company Profile

CorVel Corporation (NASDAQ: CRVL) is a technology-driven provider of workers’ compensation, liability, and specialty risk management solutions. The company develops and deploys software and data analytics tools to streamline claims administration, medical cost containment, prescription drug management, and provider network access. CorVel’s integrated platform connects employers, insurers, healthcare providers, and injured workers, aiming to improve outcomes and control costs through process automation and real-time decision support.

The company’s product suite includes claims lifecycle management, bill review and negotiation, virtual care and telehealth services, pharmacy benefit management, and independent medical examinations (IMEs).